| DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist M Thépaut, J Luczkowiak, C Vivès, N Labiod, I Bally, F Lasala, Y Grimoire, ... PLoS pathogens 17 (5), e1009576, 2021 | 167 | 2021 |
| Survey of Crimean-Congo hemorrhagic fever enzootic focus, Spain, 2011–2015 A Negredo, MÁ Habela, ER de Arellano, F Diez, F Lasala, P López, ... Emerging Infectious Diseases 25 (6), 1177, 2019 | 56 | 2019 |
| Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses P Almendro-Vázquez, M Chivite-Lacaba, A Utrero-Rico, ... Frontiers in immunology 13, 981350, 2022 | 26 | 2022 |
| Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naive and COVID-19–convalescent individuals J Luczkowiak, N Labiod, G Rivas, M Rolo, F Lasala, J Lora-Tamayo, ... The Journal of Infectious Diseases 225 (11), 1905-1908, 2022 | 17 | 2022 |
| Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses F Lasala, A García-Rubia, C Requena, I Galindo, MA Cuesta-Geijo, ... Antiviral research 186, 105011, 2021 | 17 | 2021 |
| Prime-boost vaccination with BNT162b2 induces high neutralizing activity against SARS-CoV-2 variants in naive and COVID-19-convalescent individuals J Luczkowiak, N Labiod, G Rivas, M Rolo, F Lasala, J Lora-Tamayo, ... Open Forum Infectious Diseases 8 (10), ofab468, 2021 | 10 | 2021 |
| Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines J Luczkowiak, G Rivas, N Labiod, F Lasala, M Rolo, J Lora‐Tamayo, ... Journal of Medical Virology 95 (1), e28268, 2023 | 9 | 2023 |
| Potent neutralizing activity of polyclonal equine antibodies against severe acute respiratory syndrome coronavirus 2 variants of concern J Luczkowiak, P Radreau, L Nguyen, N Labiod, F Lasala, F Veas, ... The Journal of infectious diseases 227 (1), 35-39, 2023 | 4 | 2023 |
| Optimized vaccine candidate MVA-S (3P) fully protects against SARS-CoV-2 infection in hamsters R Abdelnabi, P Pérez, D Astorgano, G Albericio, W Kerstens, HJ Thibaut, ... Frontiers in Immunology 14, 1163159, 2023 | 3 | 2023 |
| TLR7 activation in M-CSF-dependent monocyte-derived human macrophages potentiates inflammatory responses and prompts neutrophil recruitment M Simón-Fuentes, C Herrero, L Acero-Riaguas, C Nieto, F Lasala, ... Journal of Innate Immunity 15 (1), 517-530, 2023 | 3 | 2023 |
| Precision glycodendrimers for DC‐SIGN targeting G Goti, C Colombo, S Achilli, C Vivès, M Thépaut, J Luczkowiak, N Labiod, ... European Journal of Organic Chemistry 2022 (29), e202200113, 2022 | 3 | 2022 |
| Potency and breadth of neutralization after 3 doses of mrna vaccines in covid-19 convalescent and naïve individuals J Luczkowiak, G Rivas, N Labiod, F Lasala, M Rolo, J Lora-Tamayo, ... medRxiv, 2022.03. 17.22272557, 2022 | 3 | 2022 |
| Real-time RT-PCR assay to detect Granada virus and the related Massilia and Arrabida phleboviruses L Davó, L Herrero, MP Sánchez-Seco, N Labiod, D Roiz, E Gómez-Díaz, ... Parasites & Vectors 13, 1-7, 2020 | 2 | 2020 |
| Unprecedented selectivity for homologous lectin targets: differential targeting of the viral receptors L-SIGN and DC-SIGN C Delaunay, S Pollastri, M Thépaut, G Cavazzoli, L Belvisi, C Bouchikri, ... | | 2024 |
| Development of a highly selective glycomimetic ligand for L-SIGN: a new tool against SARS-CoV-2 and Ebola viruses C Delaunay, S Pollastri, M Thépaut, G Cavazzoli, L Belvisi, C Bouchikri, ... | | 2023 |
| MAFB shapes human monocyte–derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression M Simón-Fuentes, I Ríos, C Herrero, F Lasala, N Labiod, J Luczkowiak, ... JCI insight 8 (24), 2023 | | 2023 |
| Dendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2 R Lázaro‐Gorines, P Pérez, I Heras‐Murillo, I Adán‐Barrientos, ... Advanced Science 10 (34), 2304818, 2023 | | 2023 |
| Superior neutralizing response after first versus second SARS‐CoV‐2 infection in fully vaccinated individuals G Rivas, N Labiod, J Luczkowiak, F Lasala, M Rolo, M Mancheño‐Losa, ... Journal of Medical Virology 95 (11), e29225, 2023 | | 2023 |
| Interacción y relevancia biológica de la lectina DC-SIGN con la envuelta del virus emergente SARS-CoV-2 N Labiod Becerro Universidad Complutense de Madrid, 2023 | | 2023 |
| The role of DC-SIGN as a trans-receptor in infection by MERS-CoV N Labiod, J Luczkowiak, MM Tapia, F Lasala, R Delgado Frontiers in Cellular and Infection Microbiology 13, 2023 | | 2023 |
